Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.
Kimball, A B, T Kerbusch, F van Aarle, P Kulkarni, Q Li, A Blauvelt, K A Papp, K Reich, and D Montgomery. 2020. “Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Efficacy and Safety of Tildrakizumab.”. The British Journal of Dermatology 182 (1): 180-89.